New data could move Enhertu into early breast cancer

New data could move Enhertu into early breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase III trialThe post AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial appeared first on Clinical Trials Arena.

T-DXd Plus THP Bolsters Pathologic Responses in Early-Stage Breast Cancer

Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.

Enhertu Regimen Improves Responses in High-Risk HER2+ Breast Cancer

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk HER2-positive early-stage breast cancer.

T-DXd Shows Benefits in Phase 3 Early Breast Cancer Study

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast cancer, according to DESTINY-Breast11 data.

T-DXd Followed by THP Improves pCR Rate in HER2+ Early Breast Cancer

Neoadjuvant T-DXd plus THP significantly improved pCR rates in HER2+ early breast cancer.